Guidelines summarize the research and translate it into treatment recommendations. The quality of evidence and the strength of a recommendation are not the same thing. Grade A („should“) indicates a strong recommendation, while Grade B („should“) indicates a recommendation. In addition to the available studies, factors such as benefits, risks, clinical experience, and patient preferences are taken into account.
Randomized controlled trials are particularly important for assessing efficacy. Random assignment reduces systematic differences between groups, but does not eliminate every possible source of bias.
Depression. The National Clinical Practice Guideline for Unipolar Depression, Version 3.2 from July 2023, does not recommend any specific treatment: „To date, there is no evidence supporting differential indications for specific treatments for specific patients with depressive disorders.“ This is not a free pass, however, as the guideline itself includes the following caveat: „However, not every procedure is equally suitable for every patient,“ and an incorrect choice could also lead to a worsening of symptoms. A lack of evidence does not mean that the choice does not matter. According to Recommendation 4-27, this decision should be made during the consultation or in a trial setting.
Anxiety. For anxiety disorders, CBT is the standard of care: the first-line treatment with the highest level of recommendation. That is what it says in the S3 Guideline: Treatment of Anxiety Disorders, Version 2.0 dated April 6, 2021: „Cognitive behavioral therapy (CBT) should be offered (Ia/A).“ Psychodynamic treatment follows, with a recommendation level of B and subject to one condition: it should be offered „if CBT has not proven effective, is not available, or if the informed patient expresses a preference for it.“ This applies equally to panic disorder and agoraphobia, generalized anxiety disorder, and social phobia. Regarding generalized anxiety disorder, the guideline is clear: „Psychodynamic therapy appears to be inferior to CBT.“ The guideline’s own addendum belongs in the same section: „The available studies were conducted over a period of up to 30 hours.“
Compulsion. For obsessive-compulsive disorders, this very evidence is lacking. Statement 4-21 of the S3 Guideline on Obsessive-Compulsive Disorder, Version 2.0 dated June 30, 2022, states: „There is no evidence from randomized controlled trials regarding the effectiveness of these treatments.“ Recommendation 4-1, Grade A: „For obsessive-compulsive disorder, disorder-specific cognitive behavioral therapy (CBT), including exposure, should be offered as the first-line psychotherapy.“
The first-line treatment in accordance with the guidelines therefore remains disorder-specific CBT, including exposure. I have also treated people with obsessive-compulsive disorder using psychodynamic approaches, but I have never presented this approach as being equally well-supported. Understanding individual fears, conflicts, and relationship patterns can be helpful; however, it does not replace transparent information about the more well-established treatment of obsessive-compulsive symptoms.
In the standard textbook on my treatment method, Michael Ermann cites, in addition to early developmental disorders, a genetic predisposition and involvement of the frontal lobe, basal ganglia, and limbic system. He also writes that obsessive-compulsive disorders are chronic, do not resolve spontaneously, and are extremely difficult to treat.
PTSD. The S3 Guideline on Post-Traumatic Stress Disorder In its version dated February 27, 2026, it recommends, with a Grade A rating, a trauma-focused approach in an individual setting and lists five interventions with robust evidence, including Eye Movement Desensitization and Reprocessing (EMDR). Psychodynamic approaches are mentioned only in the research recommendations and among the methods whose effectiveness has not been sufficiently verified. However, many practitioners across all disciplines have additional training in trauma therapy methods.